Legal Disclaimer

This website contains information regarding adrabetadex, a pharmaceutical product that has completed clinical trials but has not received regulatory approval for commercial use. Mandos LLC, a wholly owned subsidiary of Beren Therapeutics PBC, filed a New Drug Application for adrabetadex with the FDA on December 17, 2025, and it was accepted for review by the FDA on February 13, 2026.

Any potential risks, side effects, and contraindications have not been firmly established. Please consult with a healthcare professional or relevant regulatory authority for guidance on treatment options and medications.

The efficacy, safety, and quality of adrabetadex have not yet been evaluated and validated by regulatory authorities, including the FDA. As such, any claims related to the product's benefits or outcomes should be considered preliminary and subject to change pending further review and approval by regulatory authorities including the FDA.

By accessing this website, you acknowledge that you have read and understood this disclaimer and agree to its terms.